Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial
2024

Eptinezumab's Impact on Work Productivity in Migraine Patients

Sample size: 890 publication 10 minutes Evidence: high

Author Information

Author(s): Barbanti Piero, Awad Susanne F., Rae-Espinoza Heather, Regnier Stephane A., Lee Xin Ying, Goadsby Peter J.

Primary Institution: IRCCS San Raffaele, Rome, Italy

Hypothesis

What is the impact of eptinezumab on work productivity in adults with migraine who have had prior treatment failures?

Conclusion

Eptinezumab significantly decreased absenteeism and presenteeism in migraine patients, highlighting the importance of considering the most bothersome symptom.

Supporting Evidence

  • Eptinezumab-treated patients had a modeled reduction of 7.2 hours/month in absenteeism compared to placebo.
  • Eptinezumab-treated patients experienced a reduction of 21.4 hours/month in presenteeism compared to placebo.
  • Improvements in work productivity were observed even after controlling for monthly migraine days.
  • Patients reported a substantial negative impact of migraine on work life and productivity.

Takeaway

Eptinezumab helps people with migraines work better by reducing the time they miss work and improving how well they can work when they have a migraine.

Methodology

The study used electronic diaries to capture monthly migraine days and work productivity metrics from patients in a randomized, double-blind, placebo-controlled trial.

Potential Biases

Some patients may have adjusted their schedules to accommodate migraines, potentially affecting response rates.

Limitations

The study population was primarily White and female, which may limit generalizability.

Participant Demographics

The study included adults with migraine and 2-4 prior preventive treatment failures, primarily White and female.

Statistical Information

P-Value

<0.001

Confidence Interval

95% CI: −9.9, −4.5 for absenteeism; 95% CI: −26.3, −16.5 for presenteeism

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/s41687-024-00813-w

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication